Pharmaceutical - Novo Nordisk, Markets & Marketing

Filter

Popular Filters

1 to 25 of 29 results

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

07-07-2014

Danish diabetes care giant Novo Nordisk's fixed-dose combination therapy insulin degludec/liraglutide…

DiabetesEuropeIDegLiraMarkets & MarketingNovo NordiskPharmaceuticalUSAXultophy

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

19-06-2014

Danish diabetes care giant Novo Nordisk has launched its newest prefilled insulin delivery device Levemir…

DiabetesLevemirMarkets & MarketingNovo NordiskPharmaceuticalUSA

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Novo Nordisk falls on loss of two US contracts

04-09-2013

Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Sanofi latest to be implicated Chinese bribery allegations

09-08-2013

In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Briefs: New research deals for AstraZeneca and Novo Nordisk; Lundbeck's Selincro launched in Europe

22-04-2013

Anglo-Swedish drug major AstraZeneca and BIND Therapeutics, a US clinical-stage biopharmaceutical, have…

AstraZenecaBIND TherapeuticsBiotie TherapiesEuropeKymabLundbeckMarkets & MarketingNovo NordiskOncologyPharmaceuticalResearchSelincro

Novo Nordisk debuts Tresiba in UK and Denmark

04-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has started the European roll-out of its Tresiba (insulin…

DiabetesEuropeMarkets & MarketingNovo NordiskPharmaceuticalTresiba

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord

13-02-2013

Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24-01-2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Global diabetes drugs market led by Novo Nordisk and Sanofi

14-11-2012

The global diabetes drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

DiabetesGlobalMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Russia's Renova invests in Novelos; Novo Nordisk opens Vietnam office

08-11-2012

USA-based Novelos Therapeutics (OTCQX: NVLT), which is developing novel drugs for the treatment and diagnosis…

Asia-PacificDiabetesFinancialMarkets & MarketingNovelos TherapeuticsNovo NordiskOncologyPharmaceutical

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

23-10-2012

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

Novo Nordisk and AstraZeneca among firms to invest in Russian pharma hub

11-07-2012

In Russia, the Kaluga government plans to establish a pharmaceutical manufacturing hub in the region…

AstraZenecaEuropeFinancialMarkets & MarketingMenariniNovo NordiskPharmaceuticalSTADA Arzneimittel

Ground-breaking on new Novo Nordisk plant in Russia

17-04-2012

Danish insulin giant Novo Nordisk (NOV: N) broke ground yesterday on a new $100 million plant in Russia…

EuropeFinancialInsulinMarkets & MarketingNovo NordiskPharmaceutical

Novo Nordisk tests a new business model to improve insulin access in Kenya

15-04-2012

As part of an official Danish state visit to Kenya, global insulin giant Novo Nordisk (NOV: N) last week…

DiabetesInsulinMarkets & MarketingNovo NordiskPharmaceuticalPricingRest of the World

Sanofi to top Pfizer as number one for global pharma sales

01-11-2011

French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

1 to 25 of 29 results

Back to top